Rickard Kathleen A.'s Form 4 filing
Verona Pharma plc (VRNA) · filed May 1, 2025
- Accession no.
- 0001104659-25-043646
- Filed
- May 1, 2025
- Trade date
- Aug 7, 2024-Apr 29, 2025
- Filing delay
- 267 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $308.8K. It was filed 267 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rickard Kathleen A.CIK 0001836883 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 29, 2025 | Ordinary Shares | MOption exerciseAcquired | +86,064 | $0.00 | $0 | 2,695,040 | Direct | |
| Apr 29, 2025 | Ordinary Shares | SSaleDisposed | −34,384 | $8.98F3 | −$308,768.32 | 2,660,656 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2024 | Ordinary Shares | AGrant or awardAcquired | +300,000 | $0.00 | $0 | 300,000 | Direct | |
| Apr 29, 2025 | Ordinary Shares | AGrant or awardAcquired | +253,120 | $0.00 | $0 | 253,120 | Direct | |
| Apr 29, 2025 | Ordinary Shares | MOption exerciseDisposed | −86,064 | $0.00 | $0 | 167,056 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported represents the sale price of the ADSs divided by eight (8).
Referenced by the price of 1 transaction in Table I.